NRXP

+ Watchlist + Portfolio

NRX Pharmaceuticals, Inc.

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.85
52-Week Range: $1.62 – $5.06
Market Cap: $125.77M
P/E (TTM): —
EPS (TTM): -0.58
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -63.99%
Gross Margin: 46.64%
Operating Margin: -590.46%
Profit Margin: 0.00%
Current Ratio: 0.86
Debt/Equity: —
Total Debt: $834.00K
Free Cash Flow: $-9.64M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $99.83M

NRXP Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$1.23M
Cost of Revenue	—	—	$0.00	$505.00K
Gross Profit	—	—	$0.00	$720.00K
Research & Development	$17.03M	$13.37M	$6.20M	$3.78M
Selling, General & Admin	$27.31M	$14.22M	$13.50M	$13.06M
Operating Expenses	$44.34M	$27.59M	$18.50M	$16.94M
Operating Income	-$44.34M	-$27.59M	-$18.50M	-$16.22M
EBITDA	-$39.75M	-$30.02M	-$24.89M	-$27.81M
Pretax Income	-$39.75M	-$30.15M	-$25.13M	-$28.62M
Income Tax	$0.00	—	—	—
Net Income	-$39.75M	-$30.15M	-$25.13M	-$28.62M
Diluted EPS	-6.10	-3.98	-2.36	-1.34
Diluted Shares	6.58M	7.58M	10.64M	21.40M

NRXP Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$20.05M	$4.59M	$1.44M	$7.80M
Receivables	$7.00K	$6.00K	$0.00	$161.00K
Current Assets	$25.80M	$6.88M	$3.30M	$8.89M
Total Assets	$25.82M	$7.32M	$3.65M	$12.96M
Current Liabilities	$15.59M	$19.05M	$21.86M	$28.58M
Long-Term Debt	$2.82M	—	$5.01M	—
Total Debt	$10.53M	$9.16M	$6.58M	$631.00K
Total Liabilities	$18.41M	$19.05M	$26.87M	$28.89M
Retained Earnings	-$223.00M	-$253.15M	-$278.27M	-$306.89M
Shareholders' Equity	$7.41M	-$11.73M	-$23.22M	-$15.94M
Working Capital	$10.21M	-$12.16M	-$18.56M	-$19.69M
Net Debt	—	$4.57M	$5.13M	—

NRXP Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$39.76M	-$21.66M	-$10.64M	-$14.11M
Capital Expenditure	-$10.00K	-$3.00K	—	—
Free Cash Flow	-$39.77M	-$21.66M	-$10.64M	-$14.11M
Depreciation & Amortisation	$4.00K	$5.00K	$5.00K	$143.00K
Stock-Based Compensation	$3.63M	$387.00K	$486.00K	$228.00K
Investing Cash Flow	-$10.00K	-$3.00K	$0.00	-$2.81M
Financing Cash Flow	$32.21M	$6.20M	$7.49M	$23.28M
Net Change in Cash	-$7.55M	-$15.46M	-$3.15M	$6.35M

NRXP Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$242.00K	$983.00K	$1.07M	$1.10M
Cost of Revenue	$0.00	$0.00	$97.00K	$408.00K	$631.00K	$675.00K
Gross Profit	$0.00	$0.00	$145.00K	$575.00K	$437.00K	$426.00K
Research & Development	$804.00K	$987.00K	$1.43M	$558.00K	$1.31M	$2.12M
Selling, General & Admin	$2.94M	$2.74M	$2.81M	$4.57M	$3.81M	$4.75M
Operating Expenses	$3.75M	$3.73M	$4.17M	$5.20M	$5.18M	$6.93M
Operating Income	-$3.75M	-$3.73M	-$4.02M	-$4.62M	-$4.75M	-$6.50M
EBITDA	-$5.51M	-$17.58M	-$5.85M	$1.13M	-$1.03M	-$16.11M
Pretax Income	-$5.51M	-$17.58M	-$5.89M	$360.00K	-$1.43M	-$16.52M
Net Income	-$5.51M	-$17.58M	-$5.89M	$360.00K	-$1.43M	-$16.52M
Diluted EPS	-0.34	-0.98	-0.27	—	-0.04	-0.44
Diluted Shares	16.41M	17.93M	22.23M	—	32.33M	37.65M

NRXP Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$5.55M	$2.91M	$7.18M	$7.80M	$6.71M	$26.69M
Receivables	—	—	$3.33M	$161.00K	$181.00K	$206.00K
Current Assets	$7.26M	$4.59M	$11.95M	$8.89M	$7.36M	$29.16M
Total Assets	$7.59M	$4.84M	$15.00M	$12.96M	$11.90M	$34.16M
Current Liabilities	$32.75M	$40.45M	$40.59M	$28.58M	$25.18M	$33.87M
Total Debt	$8.40M	$10.23M	$10.41M	$631.00K	$934.00K	$1.25M
Total Liabilities	$32.75M	$40.45M	$40.75M	$28.89M	$25.72M	$34.33M
Retained Earnings	-$283.79M	-$301.37M	-$307.26M	-$306.89M	-$308.32M	-$324.85M
Shareholders' Equity	-$25.16M	-$35.62M	-$25.75M	-$15.94M	-$13.82M	-$170.00K
Working Capital	-$25.50M	-$35.86M	-$28.65M	-$19.69M	-$17.82M	-$4.72M
Net Debt	$2.85M	$7.32M	$2.88M	—	—	—

NRXP Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$3.48M	-$4.03M	-$2.89M	-$3.71M	-$4.29M	-$8.88M
Free Cash Flow	-$3.48M	-$4.03M	-$2.89M	-$3.71M	-$4.29M	-$9.77M
Depreciation & Amortisation	$1.00K	-$1.00K	$43.00K	$100.00K	$165.00K	$173.00K
Stock-Based Compensation	$12.00K	$67.00K	$68.00K	$81.00K	$151.00K	$139.00K
Investing Cash Flow	$0.00	$0.00	-$2.56M	-$249.00K	-$213.00K	-$684.00K
Financing Cash Flow	$7.58M	$1.39M	$9.73M	$4.58M	$3.42M	$29.53M
Net Change in Cash	$4.11M	-$2.64M	$4.27M	$613.00K	-$1.08M	$19.97M

Market Snapshot

About

NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for pain management and psychiatric disorders. The company focuses on NMDA receptor antagonists and other neurological targets to treat conditions including post-traumatic stress disorder and chronic pain. NRX is advancing multiple drug candidates through clinical trials and regulatory pathways.